A cross-sectional analysis of 52 first-line trials found post-progression access to effective therapy correlated with OS benefit in targeted therapy but not checkpoint blockade.
Daniel Araujo, MD
Advertisement
Daniel Araujo, MD, is a genitourinary medical oncologist at the University of Florida.
Articles by Daniel Araujo, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Most Patients Prefer SC Over IV Pembrolizumab, Phase 2 Data Show
2
Gedatolisib Combinations Nearly Double PFS in PIK3CA-Mutant Breast Cancer
3
First Patients Dosed With DOC1021 in Phase 1/2 Melanoma Trial
4
FDA Grants Breakthrough Status to Olomorasib in Pancreatic Cancer
5